Pramlintide Review: Amylin Analogue Improves Blood Sugar and Weight With Good Heart Safety
This review evaluates pramlintide's efficacy as insulin adjunct therapy, showing HbA1c and weight reduction with minimal hypoglycemia, alongside cardiovascular safety data and comparison with GLP-1 receptor agonists.
Quick Facts
What This Study Found
Pramlintide with insulin reduces HbA1c and weight with minimal/no hypoglycemia in T1DM and T2DM. Mechanisms: delayed gastric emptying, glucagon suppression, appetite reduction. Cardiovascular safety appears favorable. Shares mechanisms with GLP-1 RAs.
Key Numbers
Pramlintide improves HbA1c, promotes weight loss, delays gastric emptying, suppresses postprandial glucagon; favorable CV safety profile
How They Did This
Narrative review of clinical trial evidence on pramlintide efficacy (HbA1c, weight, cognition), safety (hypoglycemia, cardiovascular), and comparison with GLP-1 receptor agonists when used as insulin adjunct therapy.
Why This Research Matters
Pramlintide fills a treatment gap: patients on insulin who still have poor control and are gaining weight. Its unique mechanism (amylin replacement) addresses diabetes pathophysiology that insulin alone cannot fix.
The Bigger Picture
Pramlintide validates amylin as a therapeutic target in diabetes. Its limitations (three daily injections) are being addressed by next-generation long-acting amylin analogues like cagrilintide, which could make amylin-based therapy more practical.
What This Study Doesn't Tell Us
Three daily injections limit adherence. Review does not include head-to-head pramlintide vs GLP-1RA trials. Weight loss is modest compared to newer GLP-1 drugs. Limited cognition data available. Pramlintide is underused in clinical practice.
Questions This Raises
- ?Would long-acting amylin analogues (like cagrilintide) produce greater benefits than pramlintide?
- ?Is pramlintide + GLP-1RA combination more effective than either alone?
- ?Should pramlintide be considered more frequently given its weight and glycemic benefits?
Trust & Context
- Key Stat:
- Fills the insulin gap Pramlintide addresses what insulin alone cannot: postprandial glucagon excess, rapid gastric emptying, and appetite — reducing both HbA1c and weight when added to insulin
- Evidence Grade:
- Moderate evidence (review of clinical trial data). Based on approved drug's clinical evidence but lacking large head-to-head comparison trials.
- Study Age:
- Published 2021. Cagrilintide (long-acting amylin analogue) is being developed to address pramlintide's dosing limitations.
- Original Title:
- A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues.
- Published In:
- Current drug safety, 16(2), 129-141 (2021)
- Database ID:
- RPEP-05510
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is pramlintide and who should consider it?
Pramlintide (Symlin) is a synthetic version of amylin, a hormone normally co-secreted with insulin. It's for diabetes patients already on insulin who struggle with blood sugar control and/or weight gain. It reduces blood sugar spikes after meals and decreases appetite.
How does pramlintide compare to GLP-1 drugs like Ozempic?
Both reduce blood sugar and weight. GLP-1 drugs are typically more convenient (weekly injection) with greater weight loss. Pramlintide requires three daily injections but targets a different pathway (amylin). Some patients benefit from combining both approaches.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05510APA
Koshy, Rithika Mary; Fernandez, Cornelius James; Jacob, Koshy. (2021). A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues.. Current drug safety, 16(2), 129-141. https://doi.org/10.2174/1574886315999201105153852
MLA
Koshy, Rithika Mary, et al. "A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues.." Current drug safety, 2021. https://doi.org/10.2174/1574886315999201105153852
RethinkPeptides
RethinkPeptides Research Database. "A Review of the Efficacy and Cardiovascular Safety of Amylin..." RPEP-05510. Retrieved from https://rethinkpeptides.com/research/koshy-2021-a-review-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.